3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
4
Thoracic
2
Breast
2
Sarcoma
1
Lymphoid
1
Head & Neck
1
Conditions
Sarcoma
7
Gastrointestinal Stromal Tumors
4
Hemangiosarcoma
3
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Melanoma
2
Lymphoma
2
Carcinoma, Non-Small-Cell Lung
2
Adenocarcinoma Of Esophagus
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Sarcoma, Alveolar Soft Part
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Neoplasms
1
Liver Neoplasms
1
Histiocytoma, Malignant Fibrous
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Glioblastoma
1
Interventions
Gemcitabine
5
Cisplatin
5
Oxaliplatin
4
pembrolizumab
3
Irinotecan
3
Carboplatin
3
Specimen Handling
2
Radiosurgery
2
Psychiatric Rehabilitation
2
Observation
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Floxuridine
2
Erlotinib Hydrochloride
2
Cyclophosphamide
2
Cetuximab
2
Bortezomib
2
Blood Specimen Collection
2
trastuzumab deruxtecan
1
tislelizumab
1
spartalizumab
1
sodium thiosulfate
1
selpercatinib
1
rucaparib
1
repotrectinib
1
pidilizumab
1
pazopanib
1
p53 peptide 264-272, human
1
motexafin lutetium
1
montanide ISA 51
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colonic Neoplasms
×
spartalizumab
×
Sarcoma
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts